Biopharma | January 23, 2026
Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
Subscribe To Our Newsletter & Stay Updated
